This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Ophthalmology Podcasts

The Macular Minute Episode 8

with Richard Gale

The Macular Minute Banner

Adverse Event Management for EYLEA® (aflibercept) 8 mg

In this

2-minute
episode, we are joined by
Richard Gale
, a Consultant Ophthalmologist at York and Scarborough Teaching Hospitals NHS Foundation Trust, to discuss
the management and minimisation of adverse events with EYLEA 8 mg in UK medical retina clinics
.

 

This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.

Prescribing information for EYLEA® (aflibercept) 8 mg

can be found here
.

Prescribing information for EYLEA® (aflibercept) 2 mg

can be found here
.

Richard Gale

Richard Gale is a Professor of Ophthalmology at York University and an Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust. He leads a team of researchers in Ophthalmology and Clinical Visual Science with particular focus on macular degeneration. Richard has published over 100 scientific papers and book chapters and is a Joint Ophthalmology Specialty Lead for the NIHR Clinical Research Network Yorkshire and Humber and holds the position of deputy chair for the National Ophthalmology Specialty Group (Northern).

 

Speaker Disclosures

Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen, 

Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen

References

  1. EYLEA® 40 mg/mL Summary of Product Characteristics.
  2. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025
The Macular Minute: Podcast Series
Your source for quick expert insights in medical retina
PP-EYL-GB-2538, January 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2548 | December 2024